Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

156.95 +9.72 (+6.60%)
Streaming Delayed Price Updated: 2:28 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $7.93 billion. On the other hand, the... 
Via StockStory
News headline image
Gilead (GILD) Q4 2025 Earnings Call Transcript ↗
Gilead (GILD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Gilead Sciences Inc (NASDAQ:GILD) Posts Strong Q4 Beat but 2026 Outlook Disappoints ↗
Via Chartmill
Gilead Sciences Inc. (NASDAQ:GILD) Passes the Caviar Cruise Quality Investing Screen ↗
Via Chartmill
GILEAD SCIENCES INC (NASDAQ:GILD): A High-Yield, Low-Payout Dividend Stock for Disciplined Investors ↗
Via Chartmill
News headline image
Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance ↗
Here's a look at the details inside Gilead Sciences' fourth-quarter earnings report. 
Via Benzinga
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 5.2% year on year to $7.93 billion. On the other hand, the... 
Via StockStory
Topics Earnings
News headline image
Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? ↗
Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light outlook. 
Via Investor's Business Daily
News headline image
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Should You Buy Gilead Sciences Before Feb. 10? ↗
Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? 
Via The Motley Fool
News headline image
Exploring Gilead Sciences&#39;s Earnings Expectations ↗
 
Via Benzinga
News headline image
Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here&#39;s How Much You Would Have Made Owning Gilead Sciences Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
This Overlooked Biotech Giant Could Surprise Investors This Quarter
Investors may be underestimating the long-term potential of Gilead’s evolving portfolio. 
Via Barchart.com
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
Via PRLog
News headline image
Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗
Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following... 
Via Talk Markets
Topics Stocks
News headline image
3 Cash-Producing Stocks with Warning Signs
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare
Via Get News
Topics Artificial Intelligence
News headline image
Are Wall Street Analysts Predicting Gilead Sciences Stock Will Climb or Sink?
Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Demystifying Gilead Sciences: Insights From 17 Analyst Reviews ↗
 
Via Benzinga
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Here&#39;s How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Earnings Preview: What to Expect
Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS. 
Via Barchart.com
Topics Artificial Intelligence ETFs Government
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.